{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T06:47:28Z","timestamp":1788850048161,"version":"build-2803163510"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.bmcl.2021.128432","type":"journal-article","created":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T22:55:58Z","timestamp":1635548158000},"page":"128432","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Design and synthesis of an oral prodrug alalevonadifloxacin for the treatment of MRSA infection"],"prefix":"10.1016","volume":"54","author":[{"given":"Satish","family":"Bhawsar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Kale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasad","family":"Deshpande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindra","family":"Yeole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Bhagwat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bmcl.2021.128432_b0005","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/antibiotics8020052","article-title":"The continuing threat of methicillin-resistant staphylococcus aureus","volume":"8","author":"Gajd\u00e1cs","year":"2019","journal-title":"Antibiotics"},{"issue":"5","key":"10.1016\/j.bmcl.2021.128432_b0010","doi-asserted-by":"crossref","first-page":"892","DOI":"10.3390\/molecules24050892","article-title":"The concept of an ideal antibiotic: implications for drug design","volume":"24","author":"Gajd\u00e1cs","year":"2019","journal-title":"Molecules"},{"issue":"10","key":"10.1016\/j.bmcl.2021.128432_b0015","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/BF01962381","article-title":"Comparative activity of the topical quinolone OPC-7251 against bacteria associated with acne vulgaris","volume":"11","author":"Vogt","year":"1992","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"4","key":"10.1016\/j.bmcl.2021.128432_b0020","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/0190-9622(91)70252-W","article-title":"Clinical and bacteriologic evaluation of OPC-7251 in patients with acne: a double-blind group comparison study versus cream base","volume":"25","author":"Kurokawa","year":"1991","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.bmcl.2021.128432_b0025","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1469-0691.2004.01017.x","article-title":"Activity of the New Quinolone WCK 771 against Pneumococci","volume":"11","author":"Appelbaum","year":"2005","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.bmcl.2021.128432_b0030","unstructured":"Patel MV, Agarwal SK, Sreenivas KG, Shetty NK, Upadhya DK, Chaturvedi N, Thomas A, De Souza NJ, Khorakiwala HF, Antibacterial optically pure benzoquinolizine carboxylic acids, processes, compositions and methods of treatment US 6,750,224 B1."},{"issue":"16","key":"10.1016\/j.bmcl.2021.128432_b0035","doi-asserted-by":"crossref","first-page":"5232","DOI":"10.1021\/jm050035f","article-title":"A Chiral Benzoquinolizine-2-carboxylic Acid Arginine Salt Active against Vancomycin-Resistant Staphylococcus aureus","volume":"48","author":"de Souza","year":"2005","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2021.128432_b0040","doi-asserted-by":"crossref","unstructured":"Bhagwat SS, Nandanwar MN, Kansagara A, Patel A, Takalkar S, Chavan R, Hariharan Periasamy, Yeole RD, Deshpande PK, Bhavsar SB, Bhatia A, Ahdal J, Jain R, Patel MV, Levonadifloxacin, a Novel Broad-Spectrum Anti-MRSA Benzoquinolizine Quinolone Agent: Review of Current Evidence, Drug Design, Development and Therapy, 2019:13 4351-4365.","DOI":"10.2147\/DDDT.S229882"},{"key":"10.1016\/j.bmcl.2021.128432_b0045","unstructured":"Patel MV, Desai VN, Deshpande PK, Yeole RD, Kale RP, Prodrugs of benzoquinolizine-2-carboxylic acid, US 2007\/0219227 A1."},{"issue":"suppl 2","key":"10.1016\/j.bmcl.2021.128432_b0050","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/jac\/39.suppl_2.87","article-title":"Oral bioavailability of trovafloxacin with and without food in healthy volunteers","volume":"39","author":"Teng","year":"1997","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.bmcl.2021.128432_b0055","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02297-17","article-title":"Intrapulmonary Pharmacokinetics of Levonadifloxacin following Oral Administration of Alalevonadifloxacin to Healthy Adult Subjects","volume":"62","author":"Rodvold","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2021.128432_b0060","unstructured":"Ivaturi V, Niu J, Chugh R, Bhatia A, Chavan R, Patel A, Takalkar S, Patel MV, Bhagwat SS, Gobburu J, Population pharmacokinetics of levonadifloxacin administered as WCK 2349, a novel oral benzoquinolizine quinolone prodrug, 55th Interscience conference of antimicrobial agents and chemotherapy (ICAAC), San Diego, California, September 17-21, 2015, Poster No A-033."},{"key":"10.1016\/j.bmcl.2021.128432_b0065","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.2147\/DDDT.S229882","article-title":"Levonadifloxacin, a Novel Broad-Spectrum Anti-MRSA Benzoquinolizine Quinolone Agent: Review of Current Evidence","volume":"13","author":"Bhagwat","year":"2019","journal-title":"Drug Design, Development and Therapy"},{"key":"10.1016\/j.bmcl.2021.128432_b0070","unstructured":"Preston RA, Chagh R, Mastim M, Shukla U, Bhatia A, Single-Center Evaluation of the Pharmacokinetics and Safety of the Novel Fluoroquinolone WCK 2349 in Hepatic Impairment. 26th European congress of clinical microbiology and infectious diseases (ECCMID), poster No 1270, 2016, 9th -12th April, Amsterdam."},{"key":"10.1016\/j.bmcl.2021.128432_b0075","unstructured":"Deshpande PK, Bhawasar SB, Joshi SN, Kale RP, Deshmukh VV, Yeole RD, Rane V, Patel MV, A process for preparation of pure (S)\u200b-\u200b(-\u200b)\u200b-\u200b9-\u200bfluoro-\u200b8-\u200b(4-\u200bhydroxysulfonyloxy-\u200bpiperidin-\u200b1-\u200byl)\u200b-\u200b5-\u200bmethyl-\u200b6,\u200b7-\u200bdihydro-\u200b1-\u200boxo-\u200b1H, 5H-\u200bbenzo[i,\u200bj]\u200bquinolizine-\u200b2-\u200bcarboxylic acid, IN 2011MU02427."},{"key":"10.1016\/j.bmcl.2021.128432_b0080","doi-asserted-by":"crossref","unstructured":"Vinod Ahirrao, Vipul Rane, Kiran Patil, Kiran More, Rajiv Jadhav, Ravindra Yeole, Reverse-phase chiral high-performance liquid chromatography for separation of a diastereomer in alalevonadifloxacin: A novel antibacterial agent, Biomedical Chromatography. 2021;35:e5079https:\/\/doi.org\/10.1002\/bmc.5079.","DOI":"10.1002\/bmc.5079"},{"key":"10.1016\/j.bmcl.2021.128432_b0085","doi-asserted-by":"crossref","unstructured":"Patil KR, Rane VP, Ahirrao VK and Yeole RD, Impurity Profiling of a Novel Anti-MRSA Antibacterial Drug: Alalevonadifloxacin, Journal of Chromatographic Science, 2020, 1\u201310, doi: 10.1093\/chromsci\/bmaa068.","DOI":"10.1093\/chromsci\/bmaa068"},{"key":"10.1016\/j.bmcl.2021.128432_b0090","doi-asserted-by":"crossref","unstructured":"Hashimoto K, Okaichi Y, Nomi D, Miyamoto H, Bando M, Kido M, Fujimura T, Furuta T, Minamikawa JA, Practical Synthesis of (S)-(\u2013)-Nadifloxacin: Novel Acid Catalyzed Racemization of Tetrahydroquinaldine Derivative, Chem. Pharm. Bull, 1996, 44, 642\u2013645.DOI: 10.1248\/cpb.44.642.","DOI":"10.1248\/cpb.44.642"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X21006594?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X21006594?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:41:58Z","timestamp":1760773318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X21006594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":18,"alternative-id":["S0960894X21006594"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2021.128432","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and synthesis of an oral prodrug alalevonadifloxacin for the treatment of MRSA infection","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2021.128432","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"128432"}}